Login to Your Account

Kythera's ATX-101 Hits Target in Two Phase III Aesthetic Trials

By Marie Powers
Staff Writer

Thursday, April 26, 2012

Kythera Biopharmaceuticals Inc. hit the bull's eye in two pivotal European Phase III trials of lead compound ATX-101, a first-in-class injectable drug to reduce what's commonly known as a double chin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription